WCD: Tofacitinib’s benefits for psoriasis persist for 2 yearsJune 11, 2015PsoriasisPsoriatic Arthritis
Anti-TNFs help psoriatic arthritis patients get back to workJune 11, 2015Psoriatic ArthritisPsoriasis
BSR: Multiple benefits seen with intensive psoriatic arthritis therapyMay 22, 2015Psoriatic ArthritisPsoriasis
Ixekizumab met psoriasis endpoints by week 12, with durable response at 60 weeksApril 9, 2015PsoriasisPsoriatic Arthritis
Secukinumab beat ustekinumab for psoriasis, with difference by week fourMarch 21, 2015PsoriasisPsoriatic Arthritis
Brodalumab achieved primary endpoints for moderate to severe psoriasis at 52 weeksMarch 21, 2015PsoriasisPsoriatic Arthritis
Data suggest link between tonsillectomy, psoriasis improvementFebruary 25, 2015PsoriasisPsoriatic Arthritis
Psoriasis treatment recommendations address four clinical scenariosJanuary 19, 2015PsoriasisPsoriatic Arthritis
Ixekizumab linked to decrease in psoriasis-related sexual difficultiesDecember 14, 2014Psoriatic ArthritisPsoriasis
Oral tofacitinib scores against psoriasis in phase III trialDecember 10, 2014Psoriatic ArthritisPsoriasis
